European Radiology:在非小细胞肺癌患者中,我们又发现了一个强有力的影像学预后标志物

2022-04-16 shaosai MedSci原创

目前的指南推荐使用[18F]FDG PET/CT对所有NSCLC患者进行初始分期。

据统计,肺癌是全世界范围内最常见的恶性肿瘤之一,占癌症死亡人数的比例最高。非小细胞肺癌(NSCLC)是肺癌最常见的组织学亚型(占所有病例的70-85%),主要有两种组织学类型:腺癌(ADC)和鳞状细胞癌(SCC)。然而,即使进行了根治性切除手术,但仍有20%至52%的I-III期患者出现局部复发或远处转移。

目前的指南推荐使用[18F]FDG PET/CT对所有NSCLC患者进行初始分期。从患者治疗前的[18F]FDG PET/CT扫描中获得的定量变量的潜在用途一直是许多研究的重要方向

经典的PET变量,如基于标准化摄取值(SUV)和基于体积的变量,如代谢性肿瘤体积(MTV)和病变总糖酵解(TLG),已被多项研究作为预测预后的重要因素,但结果并不一致。最近,文献中出现了基于测量肿瘤几何特征的新方法寻找预测预后的新的指标

近日,发表在European Radiology杂志的一项研究探讨了两个新的几何变量,即由治疗前[18F]FDG PET/CT获得的归一化SUVpeak到中心点距离(nSCD)和归一化SUVmax到周边距离(nSPD)的预后价值,与接受手术的NSCLC患者的经典代谢参数的相关性进行了比较

本项回顾性研究纳入了具有基线[18F]FDG PET/CTI-III期NSCLC患者,获得了每位患者的临床、组织病理学和代谢参数。肿瘤进行分割获得了SUV和基于体积的变量、纹理、球形度和两个新的参数,即归一化SUVpeak到中心点距离(nSCD)和归一化SUVmax到周边距离(nSPD)。早期复发(ER)和短期死亡率(STM)作为研究终点。对ER和STM进行了单变量的逻辑回归和多变量的逻辑回归。 

本研究共纳入了173名患者。在49/104名复发患者中检测到ER。此外,100名患者死亡,53名有STM。年龄、病理淋巴管侵犯、淋巴结浸润、TNM分期、nSCD和nSPD与ER相关,但在多变量分析中只有年龄(aOR = 1.06,p = 0.002)、病理淋巴管侵犯(aOR = 3.40,p = 0.022)和nSPD(aOR = 0.02,p = 0.018)是ER的重要独立预测因素。年龄、淋巴结浸润、TNM分期、nSCD和nSPD是STM的预测因素。在多变量分析中,年龄(aOR = 1.05,p = 0.006)、淋巴结浸润(aOR = 2.72,p = 0.005)和nSPD(aOR = 0.03,p = 0.022)与STM显著相关。变异系数(COV)和SUVmean/SUVmax比率对ER或STM没有显示出明显的预测价值。


 
 nSCD和nSPD与早期复发(a, b)和短期生存(c, d)之间的关系

本研究结果表明,nSCD和nSPD可作为预测NSCLC患者预后较差的预测指标,其表现优于经典的PET衍生变量。这两个参数都能识别出具有高风险的ER和STM的患者。本研究提示,将这些新的变量与临床和病理因素一起,将有助于临床建立适应风险的治疗策略。

原文出处:

Germán Andrés Jiménez Londoño,Ana Maria García Vicente,Jesús J Bosque,et al.SUVmax to tumor perimeter distance: a robust radiomics prognostic biomarker in resectable non-small cell lung cancer patients.DOI:10.1007/s00330-021-08523-3

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2060114, encodeId=420020601144f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jan 04 11:36:12 CST 2023, time=2023-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841860, encodeId=7eac184186020, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 27 04:36:12 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820026, encodeId=9dd0182002656, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Oct 10 02:36:12 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729499, encodeId=c7e91e29499e7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 31 01:36:12 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990789, encodeId=b6b21990e8985, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Dec 12 16:36:12 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542703, encodeId=5dd21542e03e3, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600910, encodeId=93c91600910cb, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2060114, encodeId=420020601144f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jan 04 11:36:12 CST 2023, time=2023-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841860, encodeId=7eac184186020, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 27 04:36:12 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820026, encodeId=9dd0182002656, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Oct 10 02:36:12 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729499, encodeId=c7e91e29499e7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 31 01:36:12 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990789, encodeId=b6b21990e8985, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Dec 12 16:36:12 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542703, encodeId=5dd21542e03e3, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600910, encodeId=93c91600910cb, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2060114, encodeId=420020601144f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jan 04 11:36:12 CST 2023, time=2023-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841860, encodeId=7eac184186020, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 27 04:36:12 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820026, encodeId=9dd0182002656, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Oct 10 02:36:12 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729499, encodeId=c7e91e29499e7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 31 01:36:12 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990789, encodeId=b6b21990e8985, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Dec 12 16:36:12 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542703, encodeId=5dd21542e03e3, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600910, encodeId=93c91600910cb, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2060114, encodeId=420020601144f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jan 04 11:36:12 CST 2023, time=2023-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841860, encodeId=7eac184186020, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 27 04:36:12 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820026, encodeId=9dd0182002656, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Oct 10 02:36:12 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729499, encodeId=c7e91e29499e7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 31 01:36:12 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990789, encodeId=b6b21990e8985, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Dec 12 16:36:12 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542703, encodeId=5dd21542e03e3, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600910, encodeId=93c91600910cb, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=)]
    2022-05-31 feather89
  5. [GetPortalCommentsPageByObjectIdResponse(id=2060114, encodeId=420020601144f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jan 04 11:36:12 CST 2023, time=2023-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841860, encodeId=7eac184186020, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 27 04:36:12 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820026, encodeId=9dd0182002656, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Oct 10 02:36:12 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729499, encodeId=c7e91e29499e7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 31 01:36:12 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990789, encodeId=b6b21990e8985, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Dec 12 16:36:12 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542703, encodeId=5dd21542e03e3, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600910, encodeId=93c91600910cb, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2060114, encodeId=420020601144f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jan 04 11:36:12 CST 2023, time=2023-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841860, encodeId=7eac184186020, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 27 04:36:12 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820026, encodeId=9dd0182002656, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Oct 10 02:36:12 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729499, encodeId=c7e91e29499e7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 31 01:36:12 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990789, encodeId=b6b21990e8985, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Dec 12 16:36:12 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542703, encodeId=5dd21542e03e3, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600910, encodeId=93c91600910cb, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2060114, encodeId=420020601144f, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jan 04 11:36:12 CST 2023, time=2023-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841860, encodeId=7eac184186020, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Fri May 27 04:36:12 CST 2022, time=2022-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820026, encodeId=9dd0182002656, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Mon Oct 10 02:36:12 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729499, encodeId=c7e91e29499e7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue May 31 01:36:12 CST 2022, time=2022-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990789, encodeId=b6b21990e8985, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Mon Dec 12 16:36:12 CST 2022, time=2022-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542703, encodeId=5dd21542e03e3, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600910, encodeId=93c91600910cb, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Fri Apr 15 13:36:12 CST 2022, time=2022-04-15, status=1, ipAttribution=)]

相关资讯

NEJM:纳武单抗+化疗作为可切除肺癌的新辅助治疗可大大改善患者预后

相比单纯化疗,纳武单抗+化疗作为可切除肺癌的新辅助治疗可大大改善患者预后

ESMO:纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%(Checkmate-816研究)

早期癌症的最终治疗目标是防止疾病复发,同时努力为患者寻求治愈的方式。不幸的是,即便接受手术治疗,仍有一半以上的可切除非小细胞肺癌(NSCLC)患者的疾病会复发,进而死亡。CheckMate-816临床

BMJ:低剂量CT筛查对肺癌患者疾病分期及生存期的影响

低剂量CT肺癌筛查方案大幅提高了I期NSCLC患者比例,延长患者生存期

ESMO:帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险(KEYNOTE-091)

3月17日,ESMO Virtual Plenary Resources发布了PEARLS/KEYNOTE-091 (NCT02504372) 研究结果。研究评估了帕博利珠单抗作为辅助治疗在完全切除的